Risk Assessment Strategy / Tools & Technology

Topic	Replies	Views	Activity
Carcinogenic Potency Database - Access free With discussions about limits and how they are establish, it’s an important reminder about the Carcinogenic Potency Database, now The Lhasa Carcinogenicity Database (LCDB). Below from Lhasa article: “5 things you should…	3	1516	August 22, 2022
About the Risk Assessment Strategy / Tools & Technology category	0	511	April 14, 2021
Risk Analysis for Ergotamine Tartrate Drug_Substance_APIs	4	262	April 22, 2024
Sitagliptin NTTP nitrosamine impurity maximum active intake level 37ng to 246.7 ng/per day	26	3394	April 2, 2024
Risk Assessment Study of Nitrosamines for the API Temozolomide Industrial Process -Pub NDSRI , featured	1	681	February 6, 2024
Application of duplex sequencing to evaluate mutagenicity -Pub NDSRI	1	206	March 14, 2024
Nitrosamines evaluation in transdermal patches featured	10	1376	March 5, 2024
Regulatory Highlights(OPR&D)	14	1704	February 28, 2024
Is it possible to observe N-nitrosamines formation from oximes? Do you have any reference to support the risk assessment for nitrosamine formation from the reaction of these functional groups in the presence of nitrosating agents? Thank you NDSRI	2	211	February 27, 2024
Skipping risk assessment	4	306	February 11, 2024
Can we bypass confirmatory testing of DP based on Theoretical Calc. of NDSRI's	5	468	February 7, 2024
QSAR Toolbox - Free software. Any experience?	17	1116	January 24, 2024
Nitrosamines risk assessment and batch results	4	335	January 23, 2024
Duplex Sequencing - Future of mutagenicity assessment	3	456	January 23, 2024
⚖️ Risk assessment not strong enough, specifically on related impurities containing secondary amine	11	855	January 19, 2024
Bard responds to Nitrosamine Risk Assessment scheme	1	491	January 16, 2024
Potential Event with USP & Health Authorities	8	639	February 2, 2024
QSAR Models - Ames/QSAR International Challenge Project - 21 teams from 11 countries QSAR	0	301	December 12, 2023
Nitrosamine in Azathioprine Drug_Substance_APIs	2	432	November 20, 2023
Risk analysis of nitrosamine impurities in liquid products (essences and flavors) Manufacturing , Excipients	2	372	November 14, 2023
Nitrosamine Risk Assessment for Purified Water Used in Manufacturing for Pilot Bio/Clinical Trial Batches	2	899	October 22, 2023
🖥 Berkeley Madonna Software for Nitrosation Kinetic Calculations	4	563	October 3, 2023
Nitrosamines risk assessments for Topical herbal extracts Manufacturing	1	389	September 20, 2023
Enhanced Ames Test Conditions for N-nitrosamines (Q&A Rev.16)	9	1943	September 13, 2023
Quantitation of Reactive Nitrosating Agents in Pharmaceutical Excipients for N‑Nitrosamine Risk Assessments Excipients	4	1002	September 7, 2023
Forced Degradation and the NAP test	3	458	September 2, 2023
N-nitrosoamides - a horse of a different color Drug_Substance_APIs	32	3327	September 1, 2023
Potency score for protected hydroxy group	2	393	August 22, 2023
Risk Assessemento of Nitrosamines in soft capsule	6	801	August 16, 2023
On the Risk of Nitrosamine Contamination during blister packaging Packaging	2	752	August 10, 2023

Carcinogenic Potency Database - Access free

With discussions about limits and how they are establish, it’s an important reminder about the Carcinogenic Potency Database, now The Lhasa Carcinogenicity Database (LCDB). Below from Lhasa article: “5 things you should…